In general, the best clinical outcomes with copper histidinate therapy in Menkes disease are dependent on early initiation plus the presence of partial ATP7A activity (Kaler, 2014); accordingly, viral gene therapy to restore working copies of ATP7A in combination with subcutaneous copper histidinate injections is currently in development (Haddad et al., 2018). This evidence concerns the gene ATP7A and Menkes disease.